A multicenter double-blind placebo-contr
โ
Dr. C. W. Olanow; S. Fahn; M. Muenter; H. Klawans; H. Hurtig; M. Stern; I. Shoul
๐
Article
๐
1994
๐
John Wiley and Sons
๐
English
โ 778 KB
## Abstract Three hundred and seventyโsix subjects with advanced Parkinson's disease participated in a prospective, doubleโblind placeboโcontrolled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemetยฎ. At 6 months, patients randomized to pergolide had a statistically singnific